Certain antiparasitics and antidepressants show promise for treating cryptococcosis, especially when combined with fluconazole.
4 citations
,
May 2023 in “Cells” Baricitinib and its combination with lonafarnib improve fat cell formation in certain genetic disorders.
16 citations
,
April 2014 in “Expert Opinion on Pharmacotherapy” Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.
January 2024 in “Journal of Crohn's and colitis” Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.
May 2026 in “Bioorganic Chemistry” March 2026 in “British Journal of Dermatology” Deucravacitinib did not significantly improve hair regrowth in alopecia areata patients.
August 2022 in “Nature Biotechnology” Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
August 2025 in “Fabad Journal of Pharmaceutical Sciences” Bicalutamide effectively treats prostate cancer but needs careful monitoring for side effects.
1 citations
,
July 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” Tofacitinib helps improve skin conditions in people with Down syndrome, especially alopecia areata.
July 2023 in “Journal of the ASEAN Federation of Endocrine Societies” Metyrapone effectively stabilizes severe Cushing's disease symptoms before surgery.
5 citations
,
July 2021 in “medRxiv (Cold Spring Harbor Laboratory)” Proxalutamide significantly lowered hospitalization rates in women with mild-to-moderate COVID-19.
1 citations
,
October 2023 in “Journal of the Endocrine Society” HIV medication ritonavir can increase the effects of nasal sprays like fluticasone, causing Cushing's syndrome.
8 citations
,
January 2020 in “Evidence-based Complementary and Alternative Medicine” Cinobufacin with chemotherapy improves treatment response and quality of life in advanced breast cancer patients while reducing some side effects.
1 citations
,
September 2023 in “Prostate International” Cervi Parvum Cornu complex improved urinary symptoms in men without major side effects.
January 2025 in “Journal of the European Academy of Dermatology and Venereology” Newer GLP-1 drugs like semaglutide may cause hair loss.
2 citations
,
March 2020 in “Cns & Neurological Disorders-drug Targets” Lurasidone is effective for bipolar depression and schizophrenia, but more safety data is needed.
May 2025 in “CPT Pharmacometrics & Systems Pharmacology” A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.
June 2023 in “Fundamental & clinical pharmacology” JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.
4 citations
,
March 2025 in “The Journal of Dermatology” Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.
116 citations
,
December 2013 in “European journal of endocrinology” Combining liraglutide and metformin helps obese women with PCOS who didn't lose weight on metformin alone to lose more weight.
December 2024 in “Cureus” Tirzepatide improved symptoms and hair regrowth in a man with folliculitis decalvans.
December 2023 in “Journal of Ayub Medical College Abbottabad” Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.
February 2026 in “The Journal of Dermatology” Ritlecitinib effectively regrows scalp, eyebrow, and eyelash hair in Asians with alopecia areata and is safe.
1 citations
,
December 2021 in “Tropical Journal of Pharmaceutical Research” Kanglaite injection with chemotherapy improves treatment and reduces side effects for advanced lung cancer.
23 citations
,
October 2024 in “British Journal of Dermatology” Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.
25 citations
,
September 2024 in “Cardiovascular Drugs and Therapy” March 2023 in “International Journal of Trichology” A man developed temporary hair loss after taking a cancer drug, which might indicate a better treatment response.
July 2017 in “Nursing2023” Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.
6 citations
,
November 2023 in “Clinical Pharmacokinetics” Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.